Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.
Indian J Pediatr. 2009 Jul;76(7):699-703. doi: 10.1007/s12098-009-0115-0. Epub 2009 Apr 16.
The purpose of this study was to evaluate the role of IGF-1 and IGFBP-3 in diagnosis of short stature children and adolescents in whom Growth Hormone Deficiency (GHD) was found.
In this cross sectional study the referred short stature children and adolescents to Namazi Hospital in Shiraz- Iran, in 2003-2005 were studied. The inclusion criteria were proved short stature based on the physical examination, weight, height, standard deviation score (SDS) of height < -2, with considering stage of puberty and predicted height in children without any genetic or chronic disorders. The exclusion criteria were any positive physical or laboratory data suggesting hypothyroidism, rickets or liver disorders. For all patients a provocative growth hormone test was performed with propranolol and L-dopa and serum IGF-1 and IGFBP-3 were measured. GHD defined as peak(cutoff) serum GH level under 10 ìg/L and low IGF-1 and IGFBP-3 considered as cutoff serum level under -2 standard deviation.
Eighty one short stature patients (39 boys and 42 girls) with mean age of 10.6 +/- 3.5 years completed the study. Seventeen patients with GHD were found and in 18 patients IGF-1 level were low. Only in 6 patients both GH and IGF-1 were low and 2 of them had low IGFBP-3. There were no correlations between the levels of GH,IGF-1 and IGFBP-3 in children with short stature due to GHD. The sensitivity and specifity of IGF-1 and IGFBP-3 in assessment of GHD were 35% and 81% for IGF-1 and 12% and 94% for IGFBP-3, respectively.
No correlations were found between GH level and serum levels of IGF-1 and IGFBP-3 in short patients and the sensitivity of those tests in assessment of GHD were poor.
本研究旨在评估 IGF-1 和 IGFBP-3 在发现生长激素缺乏症(GHD)的矮小儿童和青少年中的诊断作用。
在这项横断面研究中,对 2003-2005 年期间伊朗 Shiraz 的 Namazi 医院转诊的矮小儿童和青少年进行了研究。纳入标准为根据体格检查、体重、身高、身高标准差评分(SDS)< -2 证实矮小,同时考虑青春期阶段和儿童无遗传或慢性疾病的预测身高。排除标准为任何提示甲状腺功能减退、佝偻病或肝脏疾病的阳性体格或实验室数据。对所有患者进行了心得安和左旋多巴激发生长激素试验,并测量了血清 IGF-1 和 IGFBP-3。GHD 定义为峰(切点)血清 GH 水平< 10μg/L,低 IGF-1 和 IGFBP-3 定义为切点血清水平<-2 标准差。
81 名矮小症患者(39 名男孩和 42 名女孩)完成了研究,平均年龄为 10.6 ± 3.5 岁。发现 17 例 GHD 患者,18 例 IGF-1 水平较低。仅在 6 例患者中 GH 和 IGF-1 均较低,其中 2 例 IGFBP-3 水平较低。由于 GHD,GH、IGF-1 和 IGFBP-3 水平之间在矮小儿童中没有相关性。IGF-1 和 IGFBP-3 评估 GHD 的敏感性和特异性分别为 35%和 81%的 IGF-1,12%和 94%的 IGFBP-3。
在矮小患者中,GH 水平与血清 IGF-1 和 IGFBP-3 水平之间没有相关性,这些检测在评估 GHD 中的敏感性较差。